The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.

The FDA is reviewing new vaccines for meningitis and chikungunya and therapies for Parkinson disease and PTSD.

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

For immunocompromised individuals, antibody response to RSV vaccines is heterogeneous and about 40% do not seroconvert.

Adoption of the Acute Hospital Care at Home program is mainly limited to specific types of hospitals, according to study findings.